Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIconic Labs Regulatory News (ICON)

Share Price Information for Iconic Labs (ICON)

Share Price is delayed by 15 minutes
Get Live Data
1.70    0.10 (6.25%)
Bid:
1.55
Ask:
1.85
Spread: 0.30 (19.355%)
Market Cap: £264.88k
ICON Live PriceLast checked at - London Stock Exchange

Intraday Iconic Labs Share Chart

Settlement and CVA

30 Aug 2022 18:19

RNS Number : 6596X
Iconic Labs PLC
30 August 2022
 

For immediate release

ICONIC LABS PLC - IN ADMINISTRATION

Settlement of Disputes and Company Voluntary Arrangement

 

The Joint Administrators provide the following update on the administration, settlement of disputes and convening of a General Meeting:

Disputes with D sefton & Greencastle MediA

A Settlement Agreement has been entered into between the Company, Greencastle Media, Arch Capital Partners LLP, Mr D Sefton and the European High Growth Opportunities Securitization Fund. As a result, all litigation proceedings have been dismissed, and all claims, counter claims, including defamation claims, among the parties, have been waived or will be waived upon the CVA being approved.

 

A separate announcement has been issued relating to the retraction of claims made against David Sefton and the former directors of Iconic Labs PLC.

 

COMPANY VOLUNTRAY ARRANGEMENT PROPOSALS

Company Voluntary Arrangement ("CVA") Proposals have been finalised and are being sent out to all creditors and shareholders, together with Notices of Meetings of creditors and shareholders to consider the CVA which to be held on 22 September 2022, at 10.30 am and 2.00pm respectively. The General Meeting of Shareholders will include a Resolution to approve the CVA will be held at the offices of KWM Europe LLP, 9th Floor, 24 Monument Street, London, EC3R 8AJ. The meeting of shareholders will, if the CVA is passed, consider, in addition to a resolution to approve the CVA, resolutions to authorise the directors of the Company to allot shares and to disapply statutory pre-emption rights. These resolutions relating to the issuance of shares by the Company will be crucial to the Company's ability to raise future finance, including from the European High Growth Opportunities Securitization Fund as part of the "future funding" as described below.

A Form of Proxy must be completed, signed and received by Company's registrar, SLC Registrars, in accordance with the shareholders' circular.

 

FUTURE FUNDING

Subject to the CVA being approved and other resolutions being passed by shareholders at the General Meeting, the European High Growth Opportunities Securitization Fund have agreed to provide funding for the CVA and general working capital purposes, under existing and new facilities, subject to certain conditions precedent.

 

RE-LISTING OF SHARES

If the CVA is approved, the Board will enter into discussions with the Financial Conduct Authority with a view to the Company's suspension of shares being lifted. The Company's annual accounts for the year ended 30 June 2021 have been prepared and once audited will be published along with interim accounts to 31 December 2021.

 

ADMINISTRATION

If the CVA is approved, it is anticipated that the Administration will be brought to an end as soon as is practically possible.

 

 

30 August 2022

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCSDAFMSEESELA
Date   Source Headline
2nd Jun 20265:18 pmRNSConversion of Notes and Allotment of Shares
29th May 20267:00 amRNSTotal Voting Rights
29th Apr 202612:58 pmRNSConversion of Notes and Allotment of Shares
31st Mar 20267:00 amRNSInterim Results
27th Feb 202610:23 amRNSTotal Voting Rights
23rd Feb 20267:00 amRNSConversion of Notes and Allotment of Shares
31st Dec 202511:37 amRNSResult of AGM
8th Dec 20252:16 pmRNSNotice of AGM
23rd Oct 20252:30 pmRNSFull Year Results
12th Aug 20252:04 pmRNSUpdate on Compliance with UK Listing Rules
30th Jun 20253:27 pmRNSHolding(s) in Company
30th Jun 20253:25 pmRNSHolding(s) in Company
30th Jun 20257:00 amRNSTotal Voting Rights
9th Jun 20254:28 pmRNSConversion of Notes and Allotment of Shares
6th Jun 20259:48 amRNSConversion of Notes and Allotment of Shares
3rd Jun 20252:54 pmRNSConversion of Notes and Allotment of Shares
30th May 20254:00 pmRNSConversion of Notes and Allotment of Shares
28th May 20255:24 pmRNSConversion of Notes and Allotment of Shares
28th May 20254:54 pmRNSHolding(s) in Company
28th May 20254:52 pmRNSHolding(s) in Company
28th May 20254:50 pmRNSHolding(s) in Company
28th May 20254:48 pmRNSHolding(s) in Company
20th May 20257:30 amRNSRestoration Iconic Labs Plc
20th May 20257:00 amRNSRestoration of Trading and Funding Update
15th May 20254:18 pmRNSResult of AGM
24th Apr 20255:16 pmRNSNotice of AGM
31st Mar 20256:41 pmRNSInterim Results
31st Mar 20255:26 pmRNSRevised Results for the Year ended 30 June 2024
13th Feb 20255:55 pmRNSTransaction Terminated
7th Feb 20252:52 pmRNSNotification of Major Holdings
31st Oct 20243:57 pmRNSFull Year Results for the Year ended 30 June 2024
9th Sep 20247:00 amRNSWaiver of Event of Default
10th Jul 20244:22 pmRNSBoard Changes
28th Mar 20247:00 amRNSInterim Results
11th Mar 202412:00 pmRNSHeads of Terms Signed
29th Feb 20247:00 amRNSTotal Voting Rights
29th Feb 20247:00 amRNSSuspension of Trading
13th Feb 20242:08 pmRNSResult of AGM
7th Feb 20249:10 amRNSConversion of Notes and Allotment of Shares
19th Jan 20243:49 pmRNSNotice of AGM
4th Jan 20247:00 amRNSBoard Changes & Business and Strategy Update
29th Dec 20237:00 amRNSTotal Voting Rights
7th Dec 20238:53 amRNSConversion of Securities
4th Dec 20237:53 amRNSConversion of Securities
30th Nov 20237:00 amRNSTotal Voting Rights
17th Nov 202311:32 amRNSConversion of Securities
13th Nov 20238:40 amRNSConversion of Securities
2nd Nov 202310:35 amRNSConversion of Securities
31st Oct 20239:29 amRNSTotal Voting Rights
31st Oct 20237:00 amRNSFull Year Results for the Year ended 30 June 2023

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.